Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
1.21 4.48 98.85 409.85 329.63 258.63 243.10 293.13 299.51
Receivables
4.65 12.09 14.65 12.76 17.28 23.48 38.30 51.22 43.38
Inventory
0.30 0.88 1.24 2.22 2.02 3.98 7.94 8.14 10.25
Other current assets
0.52 — — — — — — — —
Total current assets
6.68 18.13 116.68 429.59 353.74 292.29 295.64 360.15 361.10
Property, Plant, Equpment (Net)
1.47 1.53 2.06 7.10 9.50 14.32 25.43 51.12 97.44
Long-term receivables
— 2.53 0.87 1.10 1.31 1.09 1.19 0.92 1.88
Goodwill and Intangible Assets (Total)
0.04 0.00 — — 88.92 126.35 117.34 106.23 99.57
Long-term assets (Other)
0.06 0.21 0.14 1.54 1.72 1.11 1.44 1.23 3.77
Total non-current assets
— 4.28 3.07 9.73 108.83 155.04 157.71 171.08 217.46
Total Assets
— 22.41 119.75 439.33 462.57 447.33 453.34 531.24 578.56
Accounts Payable
1.12 1.45 1.87 2.10 2.55 4.73 10.27 6.90 18.71
Accrued Expenses
— 4.57 5.78 9.11 15.48 24.36 28.95 32.56 38.29
Current Part of Debt
1.00 — 5.83 — 1.18 1.78 — 0.28 0.42
Other current liabilities
3.09 5.28 7.51 6.62 21.16 29.62 — — 1.00
Total current liabilities
5.22 6.74 15.29 20.88 24.89 36.13 47.67 49.39 68.68
Long Term Debt (Total)
19.10 24.50 19.29 — 6.90 11.53 — 10.06 9.95
Non-current Revenue (Deferred)
— 0.04 0.06 1.03 0.12 — — — —
Long Term Tax Liability (Deferred)
— — — — 0.64 0.43 0.21 1.61 2.34
Preferred Shares of Subsidiary (Mandatory, Redeemable)
— 45.00 — — — — — — —
Liabilities (Preferred Stock)
— 2.70 — — — — — — —
Non-current Liabilities (Other)
1.27 1.24 0.06 1.74 18.29 0.09 0.03 0.31 1.50
Total non-current liabilities
— 72.23 19.34 2.76 25.95 12.05 14.40 26.01 39.01
Total liabilities
25.59 78.97 34.63 23.64 50.83 48.18 62.07 75.40 107.68
Additional Paid In Capital
— 0.92 137.31 478.16 505.48 560.41 609.48 655.70 694.86
Common Stock (Net)
0.00 0.00 0.02 0.03 0.03 0.03 0.03 0.03 0.03
Retained Earnings
— (57.49) (52.21) (62.50) (93.77) (160.90) (218.37) (200.13) (224.28)
Common Equity (Total)
(50.31) (56.57) 85.11 415.69 411.74 399.15 391.27 455.84 470.87
Shareholders Equity (Total)
(15.77) (56.57) 85.11 415.69 411.74 399.15 391.27 455.84 470.87
Shareholders Equity and Liabilities (Total)
— 22.41 119.75 439.33 462.57 447.33 453.34 531.24 578.56
Shares (Common)
— 1.92 17.13 24.81 25.38 26.55 27.41 28.48 29.69
Shareholders Equity (Tangible)
— (56.57) 85.11 415.69 322.82 272.80 273.93 349.61 371.30
Net Debt
18.89 20.02 (73.72) (409.85) (321.55) (245.31) (243.10) (282.80) (289.13)
Total Debt
20.10 24.50 25.12 — 8.08 13.31 — 10.33 10.37

Fold the line items

In millions of $ except per-share values · columns are period end dates